OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Increasing molecular diversity is creating a need for the reinvention of process development and control strategies.
Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.
There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.
January 11, 2023
Messenger RNA is inherently unstable and thus requires unique solutions to protect its cohesion.
January 02, 2023
This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.
January 01, 2023
Biologic drug development requires relevant bioassays to measure and help predict cellular response.
Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.
December 22, 2022
Webinar Date/Time: Tue, Jan 24, 2023 11:00 AM EST
December 20, 2022
Sosei Heptares and Eli Lilly have entered a multi-target collaboration and license agreement in diabetes and metabolic diseases.
December 19, 2022
GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.
AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.
December 14, 2022
Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.
Particle engineering can be a resourceful tool to advance drug candidates by offering drug delivery innovation.